Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

The U.S. District Court for the Northern District of Texas just ruled in a lawsuit related to GLP-1 weight loss drugs, and the ruling has negative implications for Hims & Hers' business. Where to ...